American Veterinary Medical Association | New Texas veterinary school plan still alive American Veterinary Medical Association Plans for a proposed Texas Tech University School of Veterinary Medicine in Amarillo got a boost this spring. |
More here:
New Texas veterinary school plan still alive - American Veterinary Medical Association
At Jacobs Island Dog Park on Wednesday afternoon, Laura Tonnessen threw a stick into the river for her dog Thor. He barked enthusiastically, retrieving and dropping the stick at her feet. But in a few days, on the Fourth of July, Tonnessen knows Thors demeanor will change. The loud fireworks frighten him.
Hell hide behind furniture and act weird and whine, Tonnessen said.
Last year, Tonnessens friends pitbull, Cracker, ran away and was lost for three days because he was spooked by loud fireworks. It was traumatic to lose him for so long, Tonnessen said, and she makes sure to keep Thor inside on the holiday to prevent him from running away, too.
Michael Edwards, a student at the University of Montana, said his 130-pound great Pyrenees, Snowy, climbs into the bathtub, pulls the shower curtain closed with her mouth, and howls until the thunder storm or fireworks end.
If shes outside, she runs. They once found her about seven miles from their house, trying to escape the source of the noise. Animal shelters report that July 4-5 are their busiest days of the year.
When dogs bark, flee or cower on the Fourth of July, they are exhibiting symptoms of a panic disorder called noise phobia.
Fireworks and other loud noises terrify a fraction of all dogs, and their reactions sometimes endanger their health. Dogs may jump through windows, climb fences or run away for days to try to escape the sounds of patriotic celebration.
This phobia, which is a symptom of underlying anxiety issues, has recently been linked to a certain gene in dogs, says Dr. Leticia Fanucchi, a veterinary behaviorist at Washington State University's College of Veterinary Medicine.
Some dogs are more genetically predisposed to anxiety disorders, Fanucchi said, just like humans.
The area that is activated in our brain for fear is the amygdala, and the amygdala can be triggered long before the prefrontal cortex can process information, Fanucchi said.
Its like people who suffer from arachnophobia even if you explain that the spider won't hurt them, it activates the amygdala and makes them panic.
The amygdala is where irrational fears trigger a fight, flight or freeze response, while the prefrontal cortex controls reason and rational decision-making. Dogs panic at the sound of fireworks because they think their lives are at risk, even if they are safe at home.
Fanucchi said not all breeds of dogs carry this anxiety gene, and some are more prone to it than others. Within one breed, a dog could have the anxiety gene while another might not. This explains why some dogs dont react at all to loud noises. Those that do are typically anxious about other things, as well.
What we do know is that a good chunk of the dogs that have noise phobia do have generalized anxiety as an underlying disease, Fanucchi said. About 40 percent of the dogs that have generalized anxiety have noise phobia. So noise phobia is a big red flag that something else is going on with that dog, and it needs to be diagnosed and treated appropriately.
For this Fourth of July, its too late to start a long-term medication regimen to treat anxiety because medications typically take a few weeks to become effective, Fanucchi said. But there are other, short-term practices that can minimize dogs anxiety and keep them safe.
Creating a quiet and distracting setting for dogs can help them stay calm, said Emily Adamson, director of Organizational Advancement at the Humane Society of Western Montana. Scent therapy, like lavender spray, is popular for calming dogs, Adamson said.
Food toys and soft music (they play classical at the shelter) help distract the dogs from the source of their fear. For people who do take their dogs outside, Adamson recommends double-checking their ID tags to make sure the information is current, in case the dogs run away.
And then, theres the Thundershirt.
Dr. Lindsey Rewinkel at Pruyn Veterinary Hospital in Missoula said Thundershirts are available at pet stores and some veterinary hospitals, and serve as a dog anxiety vest.
Its a heavy fabric fashioned into a shirt that you wrap them in, Rewinkel said. Its not quite as severe as a swaddle, but the goal is to make them feel comforted. That has helped an incredible amount of dogs cope with noise phobias if they're not as severe.
Finally, there are medications vets can prescribe that sedate dogs and minimize their anxiety symptoms on the Fourth of July if none of these other practices work. Rewinkel said she always urges people to also treat the underlying anxiety issue with long-term behavioral therapy, and not just resort to medication, which can serve as a Band-Aid solution to a larger problem.
Here is the original post:
Why does your dog hate Fourth of July fireworks? It's genetic - The Missoulian
American Veterinary Medical Association | Zoo veterinarians, behind the scenes and in the field American Veterinary Medical Association For zoo veterinarians, their day-to-day work can encompass thousands of individual animals and a multitude of species. |
See the rest here:
Zoo veterinarians, behind the scenes and in the field - American Veterinary Medical Association
(Logo: http://photos.prnewswire.com/prnh/20150323/735844 )
An impact with a stone during a hunting trip: this is the reason why Tom had to be operated on the deep wound generated. The 4-year-old Italian Pointer, due to the wound position and poor post-surgery care of the owners, had to also deal with its subsequent reopening from the painful, non-secondary repercussions. Stumbling, instead, on a hooked piece of iron in the ground as he walked with his owners, Niki, a 9-year-old German shepherd, got a contused and lacerated wound that, though promptly sutured, created problems afterwards that eventually led to a surgical curettage and the removal of an already necrotic skin flap.
How to help the closure of the two wounds in a short time, without pain and contraindications? Laser therapy applied in the veterinary field turns out to be providential. Thanks to its anti-inflammatory, antiedemigenous, analgesic, and biostimulating effects, it results in a rapid healing and oedema resolution, an immediate improvement in local blood circulation, a fast recovery of the structural integrity of damaged tissues, and a significant reduction of pain in the short term. The speed of application of the treatment also has positive effects on its tolerability even for the more restless or sensitive animals.
The confirmation of the value of this therapeutic solution comes from the experience of some veterinary medicine specialists who have chosen it to treat frequent pathologies in everyday outpatient practice.
"Practicing physiotherapy in the veterinary field," explains Dr. Jane McNae of the Hong Kong Vet Clinic 'Paws in Motion.' "after careful research I chose MLS Laser Therapy by ASAlaser, because the benefits of this therapeutic laser are essential for the pain and inflammation management, and to improve the natural healing of the body in many post-operative cases in the orthopaedic and neurological fields, and in common disorders of old pets. I also practice acupuncture or acu-laser treatment using both the traditional points indicated by Chinese veterinary medicine as described in the TCVM texts, and the trigger points in the myofascial tissues of the individual animals. Even in this context, MLS is valid, allowing you to act quickly on the defined points."
The fields of use of laser therapy are many, and, besides injuries and wounds, it also speaks the language of potentially disabling pathologies.
On the subject, the words of Dr. Martha Matallana, a veterinary physician specialized in physical therapy and rehabilitation of small animals, chiropractic and ozone therapy, DMV at the Salle University of Bogot: 'The effective use of MLS Laser Therapy is extensive, and covers, for example, both patients who, after an orthopaedic operation, must be able to return to their activity in the shortest amount of time possible, and also animals that are unsuitable for surgery that have to live with acute pain coming from problems such as the infirmity of the intervertebral disc. In both cases, the time factor is crucial: MLS not only has short application times, but also offers fast recovery results ."
A non-secondary advantage that benefits pets like equine and exotic species. A comprehensive therapy already in its DNA.
SOURCE ASA Srl
Read the original here:
Laser Therapy: Amazing Results in Veterinary Medicine - PR Newswire (press release)
Write A Letter To The Editor
Letters to the editor are encouraged. Each letter must include the author's name, mailing address and daytime telephone number.
The author's name and city of residence will be used if the letter is used in print or online.
Addresses and phone numbers will not be published. Letters have a 250-word limit.
Letters may be edited for length, style and grammar. Send to letters@tulsaworld.com.
Mail to Tulsa World, Letters to the Editor, Box 1770, Tulsa, OK 74102.
For more information, call 918-581-8330 Monday-Friday from 8 a.m. to 5 p.m.
Op/ed space in the Tulsa World is limited. To preserve the space for the pieces we think our readers will most appreciate, we have these guidelines for submissions:
1. Op/eds should to be about public policy issues not personalities.
2. They should be debatable in nature: They should take a stance that some but not all of our readers would agree with.
3. They should not be in direct response to previous op/ed columns, syndicated columns, letters to the editor or Tulsa World editorials. The proper forum for such responses is our letter to the editor space.
4. They should come from authors who are authoritative on the topic or offer some unique identifiable perspective.
5. They should to be about 600 words long.
6. They cannot be election endorsements or un-endorsements, although at times the editorial department will solicit op/ed columns on both sides of an election for publication.
7. They cannot be product endorsement.
8. They should come from an author who lives within our circulation area.
9. They should not have been published elsewhere or submitted for publication elsewhere.
10. They cannot be libelous, incendiary or offensive to broad portions of our readership.
11. They should to be accompanied with an electronic photo of the author for publication.
These are not hard-and-fast rules. Sometimes, typically because of relative light demand for op/ed space, the editorial editor may waive one or more of the guidelines. At times of high demand, he may not be able to do so.
Columns should be submitted to: wayne.greene@tulsaworld.com
Follow this link:
Letter to the editor: The eyes disprove evolution theory - Tulsa World
Please enable Javascript to watch this video
NEW YORK Monty Capers says she desperately needs a pediatric wheelchair for her oldest son, 3-year-old Christopher.
"He makes me smile. He makes my heart skip a beat. He is suffering," said Capers.
Christopher Capers was born with cerebral palsy.
Right now, he is sharing a stroller with his baby sister, Malaysia, which is a tight fit for his long legs.
"He's very long for a child for his age. So it's uncomfortable for him to be positioned like this. He needs the chair for pre-school on July 7th," said Capers.
PIX11 News reached to a company with a generous spirit called Rehabco. Rehabco delivered Christopher's chair in 48 hours.
Jacqueline Kotschenrwurher is a survivor and a fighter. A domestic violence survivor, she says 10 years ago, during a fight with her husband, her husband shot her in the back. Kotschenrwurher survived the ordeal but became paralyzed.
"I'm angry. But I forgive him. Now I have make the best of my life," says Kotschenrwurher.
Now in a wheelchair, she says her home is now her world, and it's falling apart. Her bedroom walls are constantly dripping water.
"I can't sleep," said kotschenrwurher.
We reached out to the New York City Housing Authority for answers. NYCHAsays they first took care of the problem back in April.
A spokesperson for the New York City Housing Authority says,
All NYCHA residents deserve to live in well maintained homes. This reoccurring leak is unacceptable and we will find a permanent solution. A specialist will inspect the residents apartment tomorrow to find and resolve the underlying leak as quickly as possible."
NYCHA sent a team of workers to fix the wall.
Arianna Padilla, 25, from Central Islip says watching her 8-month-old son grow is her biggest joy. But Padilla was given bad news by her doctor.
She says in just a matter of months, she will lose her sight.
"I'm already experiencing problems with my vision. I can't drive and it scares me," said Padilla. Padilla needs cataract surgery in both eyes and suffers from severe diabetes.
The cost of treatment is $1500 an eye. Living paycheck to paycheck, she says she can't afford it.
"I don't have the money," said Padilla.
PIX11 News called her insurance companies and doctors and she got a call.
"Health First and my doctors will cover the surgery," said Padilla.
PIX11 News will follow Padilla every step of the way during her recovery.
If you would like to help, visit https://www.gofundme.com/arianas-eyesurgery
If you have a story reach out to Monica Morales on Facebook at monicamoralestv.
Type 2 Diabetes is a serious condition for anyone, but area Latinos, men, and youth sometimes face extra barriers to early diagnosis and management.
People with Type 2 Diabetes make insulin, but not enough or their bodies become resistant to it. If not diagnosed early or properly managed, the condition can lead to irreversible damage to major body organs such as the kidneys, eyes, blood vessels and nerves.
Latinos, African Americans, Native Americans and Asian Americans are ethnically predisposed to higher rates of Type 2 Diabetes, said Amy Knights, registered nurse, Northwest Colorado Health Diabetes educator and community health manager.
In the past, language was a barrier for Spanish speaking Latinos, Knights said.
Last year Northwest Colorado Health started a number of programs, providing on-sight interpretation and education about prevention and management by people who speak the language.
Early diagnosis and management is important to preventing disease progression and avoiding irreversible damage.
"Men are usually less likely to seek preventative care. Men tend to wait until things are really bad. The biggest barrier in this group of patients is their own attitudes towards prevention," Knights said.
The American Diabetes Association reminds men that it's important to talk about their health with doctors and to seek early intervention to avoid complications that can include erectile dysfunction.
Type 2 diabetes isn't an adults only health problem.
"More and more kids are being diagnosed with it, some as young as 10 years old," according the Centers for Disease Control and Prevention update Thursday.
The increase is due to inactivity leading to weight gain.
"Weight is still the biggest precursor to diabetes," Knights said when explaining that she's seeing more local children tested.
She believes that management is extra challenging when youth are diagnosed with the disease because it often means life style changes for the entire family.
"If you have diabetes and you are trying to make those changes, it won't happen overnight," Knights said. "So give yourself enough time to make those life style changes so that you can succeed."
Contact Sasha Nelson at 970-875-1794 or snelson@CraigDailyPress.com or follow her on Twitter @CDP_Education
Link:
Latinos, men, youth face challenges in diabetes diagnosis, management - Craig Daily Press
News & Observer | 'Smart' insulin patches developed at UNC, NCSU one step closer to market News & Observer Zhen Gu, whose team at the UNC-N.C. State Biomedical Engineering Program has been leading the effort to develop smart insulin patches for treating diabetes, co-founded a company based in Research Triangle Park two years ago with the idea of ... |
View post:
'Smart' insulin patches developed at UNC, NCSU one step closer to market - News & Observer
FRIDAY, June 30, 2017 (HealthDay News) -- Almost half of people with type 1 diabetes are still producing some insulin more than a decade after being diagnosed with the disease.
The new findings challenge previous assumptions that people with type 1 diabetes lose the ability to produce any insulin -- a hormone that helps usher sugar to cells to be used as fuel -- over time.
Researchers at Sweden's Uppsala University, led by post-doctoral researcher Daniel Espes, reached their conclusions after studying more than 100 patients with type 1 diabetes.
The investigators found that people who still produced insulin despite their long-standing type 1 diabetes had higher levels of a protein called interleukin-35. This protein appears to play an important role in the immune system.
Past research had shown that both newly diagnosed people with type 1 diabetes and those who've had the disease for some time had lower average levels of interleukin-35 compared to healthy people.
Type 1 diabetes is an autoimmune disease that causes the body's immune system to mistakenly attack healthy cells in the pancreas that make insulin.
This leaves people without enough insulin to meet the body's daily needs. To survive, people with type 1 diabetes must replace that lost insulin through multiple daily injections or through a tiny tube inserted under the skin every few days and then attached to an insulin pump.
The Uppsala researchers have launched a new study to see if they may be able to boost insulin production in those people with type 1 diabetes who are still making insulin.
The study appears in the June issue of Diabetes Care.
For more about type 1 diabetes, visit JDRF.
Read more:
Many People With Type 1 Diabetes Still Make Some Insulin - Sioux City Journal
TheHorse.com | How Newborn Foals' Dental Pulp Can Help Heal Horses TheHorse.com It is the most primitive form of stem cell tissue and has the greatest potential for developing into bone, ligaments, blood vessels, and more. Bertone and colleagues recently tested the effectiveness of dental pulp treatment in 20 lame horses with ... |
Here is the original post:
How Newborn Foals' Dental Pulp Can Help Heal Horses - TheHorse.com
NightstaRx has raised 39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness.
NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the clinic, the company has closed a Series C round with$45M (39.5M) that will go towards progressing its pipeline.The fundraising was backed by existing investors Syncona, the VC arm of the UKs Wellcome Trust, and New Enterprise Associates (NEA), which were joined by two new names: Wellington Management and Redmile.
NightstaRx has announced the money will fund an upcoming Phase III trial with its lead candidate NSR-REP1 in choroideremia, an ongoing Phase I/II study in X-linked retinitis pigmentosa and a planned Phase I/II program for inherited macular dystrophy.All indications pursued by the company have no effective treatment approved.
The biotechs technology is based adeno-associated virus (AAV) vectors that deliver functional genes to patients with mutations that affect their sight. The DNA is delivered via an injection under the retina as a one-time treatment.
NightstaRx lead candidate, NSR-REP1, delivers a copy of the REP-1 gene, which encodes a protein involved in absorbing nutrients. Mutations in this gene, located in the X chromosome, cause choroideremia, a rare disease in which the retina degenerates slowly over the years, eventually leaving patients blind.A previous Phase I/II trial with NSR-REP1 in six patients with choroideremia where only one eye was treated showed significant improvementin their vision three and a half years after receiving the therapy.
Gene therapy is particularly suited to treat the eye, where it can sustain long-lasting gene expression without inducing an immune response, which has led many companies to develop their own approaches for multiple diseases affecting this organ. One of the most advanced is Spark Therapeutics, in the US, which expects FDA approval for its lead candidate in retinal disease this year. A second candidate, SPK-7001, is in Phase I/II for choroidemia, where it might have to compete with NightstaRx.
In Europe, most efforts are found in France. From there, GenSight is running two Phase III trialsin the rare genetic disease LHON;Horama is in Phase I/II in another rare condition, LCA; and Eyevensys will soon start a first trial in uveitis with the first gene therapy that does not use viral vectors.
Images via GeK / Shutterstock; NightstaRx
Visit link:
40M in Series C for a British Biotech Treating Blindness with Gene Therapy - Labiotech.eu (blog)
NightstaRx has raised 39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness.
NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the clinic, the company has closed a Series C round with$45M (39.5M) that will go towards progressing its pipeline.The fundraising was backed by existing investors Syncona, the VC arm of the UKs Wellcome Trust, and New Enterprise Associates (NEA), which were joined by two new names: Wellington Management and Redmile.
NightstaRx has announced the money will fund an upcoming Phase III trial with its lead candidate NSR-REP1 in choroideremia, an ongoing Phase I/II study in X-linked retinitis pigmentosa and a planned Phase I/II program for inherited macular dystrophy.All indications pursued by the company have no effective treatment approved.
The biotechs technology is based adeno-associated virus (AAV) vectors that deliver functional genes to patients with mutations that affect their sight. The DNA is delivered via an injection under the retina as a one-time treatment.
NightstaRx lead candidate, NSR-REP1, delivers a copy of the REP-1 gene, which encodes a protein involved in absorbing nutrients. Mutations in this gene, located in the X chromosome, cause choroideremia, a rare disease in which the retina degenerates slowly over the years, eventually leaving patients blind.A previous Phase I/II trial with NSR-REP1 in six patients with choroideremia where only one eye was treated showed significant improvementin their vision three and a half years after receiving the therapy.
Gene therapy is particularly suited to treat the eye, where it can sustain long-lasting gene expression without inducing an immune response, which has led many companies to develop their own approaches for multiple diseases affecting this organ. One of the most advanced is Spark Therapeutics, in the US, which expects FDA approval for its lead candidate in retinal disease this year. A second candidate, SPK-7001, is in Phase I/II for choroidemia, where it might have to compete with NightstaRx.
In Europe, most efforts are found in France. From there, GenSight is running two Phase III trialsin the rare genetic disease LHON;Horama is in Phase I/II in another rare condition, LCA; and Eyevensys will soon start a first trial in uveitis with the first gene therapy that does not use viral vectors.
Images via GeK / Shutterstock; NightstaRx
Here is the original post:
40M in Series C for NightstaRx to Treat Blindness with Gene Therapy - Labiotech.eu (blog)
"One of the biggest obstacles is our own perceptions of our capabilities, and part of the Lighthouse's mission is to change perceptions of the abilities of the blind in all fields." Bryan Bashin, CEO, The Lighthouse for the Blind and Visually Impaired
Instead, Ojok Simon wants them to know about a way they can earn money without leaving home: beekeeping. Simon, 36, became visually impaired after he was severely beaten by rebels who came to his village when he was a child. He has been a beekeeper for 15 years, and in 2013 he co-founded Hive Uganda, an organization that teaches advocates for visually impaired people and teaches them to make a living raising honeybees.
This year, his organization will receive a boost: Simon is one of three winners of the first-ever Holman Prize, started by The Lighthouse for the Blind and Visually Impaired in San Francisco.
"It's like a blind Fulbright," said Will Butler, the organization's communication director, of the award, which gives up to $25,000 apiece to blind and visually impaired people seeking funding for ambitious personal projects.
The prize is named for James Holman, a 19th-century English navy lieutenant who lost his sight at 25. In those days, if a military man became blind, "the usual thing was they'd go sit in a convent or church and pray for the souls of dead English soldiers and sailors," said Bryan Bashin, The Lighthouse's CEO.
Holman didn't think that sounded like fun. So, "at a time with people didn't even think that blind people could get out of the house, he began to travel, and he became the most traveled blind person of the 19th century," eventually crossing through Scotland and France, and across Siberia, Bashin said.
Along the way she will videotape her encounters and blog about her journey. Her goal, she said, is "to show that blind people and other disabled people have got lots of get up and go and ability, and they are a great resource for the rest of the community, the rest of society, and particularly employers, to use better."
Melville-Brown was thrilled to learn she had won ("My thinking is it's a cross between the Paralympics and The Apprentice, with a whiff of the Nobel!" she wrote to the organizers in an excited email). But she also said the honor comes with "a great responsibility. Because I am sort of representing lots of blind people, and especially those who were candidates for the prize. I'm sort of doing it on their behalf."
Two-hundred and two applicants from 27 countries and 35 U.S. states submitted 90-second video pitches for their projects.
"We were staggered by the amount of interest and the quality and diversity of the proposals," Bashin said. "One of the biggest obstacles is our own perceptions of our capabilities, and part of the Lighthouse's mission is to change perceptions of the abilities of the blind in all fields."
Winners will be flown to San Francisco and work with the project manager to refine their ideas. A year later, they will return to report on how they turned out.
In the Gulu district of northern Uganda, Simon's organization has already taught 38 people to be beekeepers, using local materials to make beehives and learning how to understand bees' behavior.
Ugandans prize the insects for their honey, their wax (used in soap and cosmetics), their propolis, and even their venom, which can be used to boost immunity. But much of the harvesting is done in the wild, which presents a challenge for the visually impaired. Hive Uganda teaches people to use frames and assess the honey harvest by feeling how heavy they are.
Winning the Holman will allow Simon to widen the scope of how many people he can help.
"I feel that now I'm going to be addressing the larger society ... to empower East Africa in general," he told the Washington Post. "My dream is becoming reality, and that change that I wanted, I started feeling at my fingertips."
See the original post:
Blindness does not stop this beekeeper, baker, and kayaker from expanding their vision - The Guam Daily Post
Biotechnology varieties of corn and soybeans make up 95 percent of the 15.5 million acres planted this spring by Nebraska farmers, according to a report from the USDAs National Agricultural Statistics Service on Friday.
According to the report, Nebraska corn growers planted 9.8 million acres, down 1 percent from last year. Biotechnology varieties were used on 96 percent of the area planted, up 1 percentage point from a year ago. Growers expect to harvest 9.5 million acres for grain, which is down 1 percent from last year.
Statewide, soybean planted area is estimated at 5.7 million acres, up 10 percent from last years total and a record high. Of the acres planted, 94 percent were planted with genetically modified, herbicide resistant seed, down 2 percentage points from a year ago. Acres expected to be harvested are 5.65 million, up 10 percent from a year earlier.
Last year, Nebraska ranked sixth in the nation in harvested acres of principal crops at 19,223,000 acres.
Nationwide, the USDA reported that corn planted area for all purposes in 2017 is estimated at 90.9 million acres, down 3 percent from last year. Compared with last year, planted acres are down or unchanged in 38 of the 48 estimating states. Area harvested for grain, at 83.5 million acres, is down 4 percent from last year.
Soybean planted area for 2017, nationwide, is estimated at a record high 89.5 million acres, up 7 percent from last year. Compared with last year, planted acreage intentions are up or unchanged in 24 of the 31 estimating states.
The USDA reported that winter wheat seeded in the fall of 2016 totaled 1.11 million acres, down 19 percent from last year and a record low. Harvested acreage is forecast at 1 million acres, down 24 percent from a year ago.
Along with declining wheat acres, Nebraska wheat farmers are also having to deal with a wheat virus outbreak that has reached epidemic levels and has been damaging fields and yields in the southern Nebraska Panhandle, according to the Associated Press. The Nebraska Wheat Association earlier this month reported that as many as 85 percent of southern Panhandle fields have been affected by the virus.
Nationwide, all wheat planted area for 2017 is estimated at 45.7 million acres, down 9 percent from 2016. This represents the lowest all wheat planted area on record since records began in 1919. The 2017 winter wheat planted area, at 32.8 million acres, is down 9 percent from last year. Of this total, about 23.8 million acres are hard red winter.
For other Nebraska crops, the USDA reported that:
Alfalfa hay acreage to be cut for dry hay is at 770 thousand acres, up 3 percent from 2016. Other hay acreage to be cut for dry hay is 1.70 million acres, unchanged from last year.
Sorghum acreage planted and to be planted, at 140 thousand acres, is down 30 percent from a year ago. The area to be harvested for grain, at 110 thousand acres, is down 37 percent from last year.
Oats planted area is estimated at 115 thousand acres, down 15 percent from the previous year. Area to be harvested for grain, at 25 thousand acres, is unchanged from a year ago.
Dry edible bean planted acreage is estimated at 150 thousand acres, up 9 percent from last year. Harvested acres are estimated at 139 thousand acres, up 14 percent from the previous year.
Proso millet plantings of 130 thousand acres are up 37 percent from a year ago.
Sugarbeet planted acres, at 49.7 thousand, are up 4 percent from last year.
Oil sunflower acres planted are estimated at 55 thousand, up 90 percent from last year. Non-oil sunflower planted acreage is estimated at 6 thousand acres, down 52 percent from a year ago and a record low.
Dry edible pea estimated planted acres are 45 thousand acres, down 18 percent from last year. Harvested acres are estimated at 42 thousand, down 19 percent from the previous year.
See the article here:
Biotechnology crops dominate Nebraska crop fields - Grand Island Independent
SAN ANTONIO, TEXAS--(Marketwired - June 30, 2017) - Nerium Biotechnology, Inc. ("Nerium" or the "Company") is pleased to announce the voting results of its annual meeting of shareholders (the "Meeting") held on June 29, 2017 in Toronto, Ontario, Canada. This year's Meeting had extraordinary participation from Nerium's shareholders, with a total of 31,272,131 common shares, or approximately 85.75% of the outstanding common shares of Nerium, having been voted at the Meeting.
We are pleased to announce that Nerium's shareholders voted to elect all six of Nerium's director nominees to the board of directors (the "Board"). Each Nerium director nominee received at least 77% of the votes cast by shareholders present in person or represented by proxy at the Meeting. The dissident's director nominees each received 20% of the votes cast by shareholders, which includes the 7.48% of the votes cast by the dissident shareholders. The voting results of the election of directors are as follows:
"We thank Nerium's shareholders for their consideration and support during this process," said Richard Boxer, Chair of the Special Committee of Nerium's Board. "We are pleased that the Company's shareholders voted overwhelmingly to reject the dissident's nominees and elect all of Nerium's nominees to the Board. Your directors will continue to act in the best interests of Nerium and all of its shareholders, and are committed to addressing legitimate shareholder concerns. We intend to provide shareholders with a more detailed update on the Company's business in the coming weeks."
All other matters set out in the Company's management information circular were approved by the requisite majority of the shareholders at the Meeting.
About Nerium Biotechnology, Inc.
Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.
Forward Looking Statements: Statements made in this press release that relate to future plans, expectations, events or performances are forward looking statements. Forward-looking statements are not based on historic facts, but rather on current expectations regarding future events. They are based on information available to management and/or assumptions management believes are reasonable. Many factors could cause future events and outcomes to differ materially from those discussed in the forward-looking statements. Although the forward-looking statements are based on what management believes are reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof and, except as required by applicable securities laws, the Company does not assume any obligation to update or revise such forward-looking statements. More information about the Company is available in its disclosure documents, all of which are available on the Company's issuer profile on SEDAR at http://www.sedar.com.
Biotechnology Separation Systems Market
Overview
The report on the Global Biotechnology Separation Systems Market 2017 gives complete view of the market across the globe. In-depth analysis comprising key market players, market forecasts, supply, demand, profit, latest market trends, and many more are provided in the report below. The future aspects impacting the global market in every possible way are also further discussed in the report.
What our report offers:
View Free Sample Report @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#RequestSample
Biotechnology Separation Systems Market: Research methodology
To Know More, Ask Our Expert @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#InquiryForBuying
Additional information provided in the report
In addition, considering that the global economy is ever-changing depending upon several factors , it is important to take a note that our report contains data that are not only conducted regarding CAGR forecasts but it also analyzes the key parameters such as yearly market growth in order to have complete information about the future of the market worldwide. It also helps in identifying the wide opportunities that will open up for the market. The other key feature included in this report is the analysis of the revenue forecasts of all the important regions and applications, which is in terms of dollars.
About Market research Store
Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.
Contact Us:
Joel John 3422 SW 15 Street, Suit #8138, Deerfield Beach, Florida 33442, USA USA Tel: +1-386-310-3803 GMT Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: sales@marketresearchstore.com Web: http://www.marketresearchstore.com/
Read this article:
Biotechnology Separation Systems Market 2017 Industry Analysis ... - World Of WallStreet
Question: I have an old mixed-breed dog that has had arthritis for years and it has gotten to the point where he needs my help to get up off the floor. It is getting very hard for me to lift him. He took many different NSAIDS in his life, but now his kidneys and liver are not good, so we decided to take him off of those since they can cause more damage. We tried Tramadol and Gabapentin, but they did not help and just made him loopy. I read about a new drug for dogs called Galliprant. I asked my vet about it but he did not know anything. Would it help my Snoopy without hurting him?
Answer: It is not uncommon for dogs to have deteriorating kidney and liver function as they age. They often have stiff, aching joints as well.
We have been blessed with many good NSAIDs (non-steroidal anti-inflammatory drugs) to help decrease inflammation and pain. These drugs have been lifesavers for many dogs, and have allowed them to live longer happier lives. Unfortunately, they do have limitations and can cause gastrointestinal issues, like ulcers or vomiting, but more importantly, they are filtered through the kidneys and liver, and complications can develop if the function of these organs are compromised. This is why routine blood testing is mandatory when your dog is taking NSAIDS.
Galliprant is a new class of non-COX inhibiting NSAID medications that are used to treat osteoarthritis pain in dogs. Plumbs Veterinary formulary says: It could potentially cause significantly fewer severe adverse effects in dogs than other NSAIDS. The main side effect is diarrhea or vomiting.
Since Galliprant is a new class of osteoarthritis medication, long-term experience is somewhat limited. Most patients that have been placed on it long term are elderly dogs that have failed all other alternatives. Most owners report that their dogs response to the medication has been very good especially with the response in their dogs comfort level and increased mobility. I would feel very comfortable using this medication on my elderly dog.
View original post here:
New drug Galliprant a good option for elderly dogs with arthritis - Palm Beach Post
SAN FRANCISCO San Francisco-based fashion designer Yuka Uehara will lead the Arthritis Foundations 15th Annual Fashion Fights Arthritis Friday, October 20, at the Fairmont Hotel in San Francisco.
The Arthritis Foundations Fashion Fights Arthritis is a community-driven fundraiser and a fun, lighthearted way of talking about the seriousness of arthritis the nations leading cause of disability.
More than 50 million adults and 300,000 kids in the U.S. have arthritis, including 5.9 million adults in California alone. The disease costs the U.S. economy $128 billion annually and limits activity more than heart disease, cancer or diabetes.
This years event will feature a thrilling runway show featuring Yuka Ueharas Tokyo Gamine Haute Couture line, and will offer a champagne reception, silent auction, luncheon and a live auction.
All proceeds support the Arthritis Foundations mission to conquer and cure arthritis.
Tickets are now on sale online at http://www.arthritis.org/FashionFightsArthritis or call 415-356-5484 for more information.
Yuka Uehara is a Japanese-born, San Francisco-based fashion designer.Originally a medical student, Uehara began working in design when her father, filmmaker Ryuji Fukuyama, hired her to work in the costume department of his productions.
She has been working in fashion ever since, teaching herself both design and craft. Film and storytelling still informs her creative practice as she is a firm believer in the relationship between costume and character.
Fashion sends a message about who you are and where you come from. It is for that reason that Uehara has a close bond with her clients, making items that work in harmony with their personas, strengthen their narratives. Every woman is the protagonist of her own story, Uehara exclaims, Fashion is there to encourage that.
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.
See the article here:
Fashion Fights Arthritis '17 comes to San Francisco Oct. 20 - Inquirer.net
Reader Charles Wang wrote to ask if stem cell therapy - the use of stem cells to treat various medical conditions - is approved in Singapore. Mr Wang also asked where one could seek this treatment if it is available. Health reporter Linette Lai answered.
Any new treatment must be backed up by sufficient scientific evidence to ensure that it is safe and effective. However, there is still not enough scientific evidence available for stem cell therapy to be approved as a mainstream treatment in Singapore.
A Ministry of Health spokesman said: "To date, stem cell therapy has not been substantiated by sufficient clinical evidence as a form of mainstream treatment for any diseases or ailments, and it is not available as a treatment in our public hospitals.
"If any registered medical practitioners or institutions want to administer stem cells as a form of medical treatment, it would have to be conducted within the context of clinical trials."
View post:
Is stem cell therapy approved in Singapore? - The Straits Times
LUCY Clarke was facing a downhill spiral when she flew to Russia to undergo a cutting edge stem cell transplant.
Two years on she says the procedure not only halted her illness in its tracks, but reversed much of the damage inflicted by multiple sclerosis.
The 41-year-old from Inverness is now backing crowdfunding efforts so that her friend and neighbour, Rona Tynan, can receive the same life-changing operation in Mexico before she becomes too ill to qualify.
Mrs Tynan, 50, has until the end of August to raise the 60,000 needed.
However, both are angry at a cross-border divide which means that a small number of MS patients in England can undergo the treatment for free on the NHS, while in Scotland despite having some of the highest rates of MS in the world the health service has refused patients' funding and no clinical trials are planned.
Mrs Clarke, a chemistry graduate and acupuncturist, began investigating AHSCT (autologous haematopoietic stem cell transplantation) in 2014 after her condition progressed from relapsing-remitting to secondary progressive MS. At the time her son was three and she feared ending up in a wheelchair.
Although the treatment has been available overseas for decades, it has never been routinely available on the NHS and is considered unproven by many neurologists.
It is also a highly aggressive therapy, using intensive chemotherapy to strip out sufferers faulty immune systems before replenishing it with stem cells harvested from their own bone marrow or donor tissue. Despite the risks, many patients including Mrs Clarke credit it with transforming their lives.
She underwent the procedure in Moscow over a period of four weeks in April and May 2015. She said: From when my son was three to when I had the transplant, my walking had deteriorated, I needed to use a walking stick all the time, I had very poor balance, debilitating fatigue, I had brain fog, I used to slur my words.
"Im left-handed and my left hand was really weak so my writing was bad. Other things would come and go numbness in my legs, tingling, cramps in my calves, sore and painful legs. The majority of them have gone since the transplant.
I noticed quite quick improvements in things like balance. The biggest thing is not really having fatigue, and the brain fog completely went. I stopped slurring my words quite quickly after treatment. I was more alert. I had more concentration, more focus. Within six months the shaking in my left arm had gone. Ive still got drop foot in my right leg and I still use a walking stick, but once youve got to the stage of secondary progressive it all gets a bit scary. Things are going downhill and youre told theres nothing that can be done, so really my goal from treatment was just to halt the progression to know I wasnt getting any worse. Thankfully, and luckily, I have seen lots of benefits.
Eighteen months on, MRI brain scans show no signs of disease progression and while Mrs Clarke stresses that the treatment is neither a magic bullet nor a walk in the park, she is supporting Rona Tynans bid to undergo the same surgery in October.
Mrs Tynan, a retired Metropolitan police sergeant and mother-of-two from Inverness, also has secondary progressive MS. She is already in a wheelchair and fears that unless she undergoes the treatment soon she will become too ill. She said: Im a 7.5 out of 10 on the disease progression scale, where 10 is death. Most clinics stop taking you at seven, but Mexico just raised it to 8.5. Thats brilliant for people like myself, but I cant afford to get any more ill.
So far, Mrs Tynans fundraising page on JustGiving has raised nearly 4000, but she is frustrated that more is not being done to help Scottish patients. In England, clinical trials are ongoing in London and Sheffield but a small number of patients with relapsing-remitting MS can be referred for the treatment off-trial, for free, on the NHS. In Scotland, however, eligible patients have been turned down for NHS funding.
Mrs Tynan said: It seems crazy to me that Brits are going to Chicago and Mexico and Russia for a treatment that in the long-run could save the NHS loads of money. Scotland is one of the worst places in the world for MS yet in England you can get this treatment for free. Why arent we fighting in Scotland to get this?
Mrs Clarke added: Its very unfair. It just seems a no brainer to me why they wouldnt make it available not for all patients but for some. The Scottish Government said referral decisions were "for clinicians".
A spokesman said: "Whilst the vast majority of healthcare provided by NHS Scotland is delivered in Scotland, NHS boards can commission treatment in other countries on an ad hoc basis, particularly where highly specialised treatment is involved. Decisions to refer patients are for clinicians, based on agreed guidelines, which ensure best practice, equity of access and consistency of treatment for all patients.
"HSCT is not currently widely available anywhere on the NHS, but people from Scotland can participate in trials held in other centres across the UK, where clinically determined appropriate and beneficial."
Originally posted here:
Anger as Scots patients miss out on 'breakthrough' stem cell therapy ... - Herald Scotland